Skip to content

UnitedHealthcare

Does UnitedHealthcare cover Wegovy for Liver Disease (MASH)?

Yes. UnitedHealthcare covers Wegovy for liver disease (MASH) with prior authorization. Other policy requirements and your plan's benefits also apply.

Policy document

  • Employer and ACA Marketplace: Covered with requirements. See the qualification pathways below.

Earliest policy review June 2, 2026. How we verify · Check your exact plan

Full requirements: Wegovy for Liver Disease (MASH) (2 plan types)

Applies to Employer and ACA Marketplace plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

MASH Initial Authorization

All of:

  • Wegovy injection requested for treatment of MASH (formerly NASH)
  • Disease confirmed as fibrosis stage F2 or F3 by qualifying diagnostic method
  • Used in combination with reduced calorie diet and increased physical activity
  • Provider attests Wegovy injection will not be initiated simultaneously with Rezdiffra (resmetirom) for the same indication
  • Prescribed by or in consultation with gastroenterologist or hepatologist

Plus any one of:

  • Liver stiffness measurement by VCTE (e.g., FibroScan)
  • Liver stiffness measurement by MRE
  • Liver biopsy within the past 12 months

MASH Reauthorization

All of:

  • Documentation of positive clinical response to Wegovy injection (e.g., improvement in or stabilization of fibrosis)
  • Patient has not progressed to cirrhosis
  • Used in combination with reduced calorie diet and increased physical activity
  • Prescribed by or in consultation with gastroenterologist or hepatologist

Documentation to bring

  • Medical records documenting MASH diagnosis (formerly NASH)
  • Documentation of fibrosis stage F2 or F3 confirmed by one of: liver stiffness measurement via VCTE (e.g., FibroScan), liver stiffness measurement via MRE, or liver biopsy within the past 12 months
  • Provider attestation that Wegovy injection will not be initiated simultaneously with Rezdiffra (resmetirom) for treatment of MASH
  • Documentation that treatment is prescribed by or in consultation with a gastroenterologist or hepatologist

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • Renewal: Reauthorization requires: (1) documentation of positive clinical response (e.g., improvement in or stabilization of fibrosis), AND (2) patient has not progressed to cirrhosis, AND (3) continued use with reduced calorie diet and increased physical activity, AND (4) continued prescribing by or in consultation with gastroenterologist or hepatologist. Fibrosis stage confirmation (imaging/biopsy) is NOT re-checked at reauthorization.

Not covered when

  • Cirrhosis (noncirrhotic MASH only; patients who progress to cirrhosis are excluded at reauthorization)
  • Concurrent initiation of Rezdiffra (resmetirom) for MASH

Policy note: Only Wegovy injection (not tablets) is covered for MASH. Imaging lookback period is not specified for VCTE/MRE — only liver biopsy has an explicit 12-month lookback. The policy covers moderate to advanced fibrosis (F2-F3) consistent with FDA labeling. Added to program in November 2025.

Policy effective May 1, 2026 · verified June 2, 2026 · source: PA Non Formulary Wegovy · View policy document (PDF)

Open on its own page →

Questions people ask
Does UnitedHealthcare cover Wegovy?
Yes. UnitedHealthcare covers Wegovy for liver disease (MASH) with prior authorization. Other policy requirements and your plan's benefits also apply.
How long does a Wegovy approval last with UnitedHealthcare?
Liver Disease (MASH) — Applies to Employer and ACA Marketplace plans. Initial approval: 12 months. Renewal: every 12 months.
What does UnitedHealthcare require to renew Wegovy?
Liver Disease (MASH) — Applies to Employer and ACA Marketplace plans. Reauthorization requires: (1) documentation of positive clinical response (e.g., improvement in or stabilization of fibrosis), AND (2) patient has not progressed to cirrhosis, AND (3) continued use with reduced calorie diet and increased physical activity, AND (4) continued prescribing by or in consultation with gastroenterologist or hepatologist. Fibrosis stage confirmation (imaging/biopsy) is NOT re-checked at reauthorization.
How current is this information?
The oldest review date among the policies on this page is June 2, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Also under UnitedHealthcare: Mounjaro, Ozempic, Zepbound

Wegovy under other plans: Aetna, Centene, Cigna, Medicare GLP-1 Bridge (CMS), Alabama Medicaid, BCBS Alabama, BCBS Arizona, BCBS Arkansas

All insurance plans · All medications

Summary of UnitedHealthcare's written policy, not a guarantee of coverage. Plans vary by employer and benefit design.